Prospects for in vitro myofilament maturation in stem cell-derived cardiac myocytes

Biomarker Insights

Volumn 10, Issue , 2015, Pages 91-103

  Schwan, Jonas ^a   Campbell, Stuart G ^a  

^a Yale University   (United States)

Author keywords

Cardiomyopathy; Disease modeling; Engineered heart tissue human pluripotent stem cell derived cardiomyocytes; Maturation; Protein isoforms

Indexed keywords

CALCIUM; CONNECTIN; ISOPROTEIN; MYOSIN HEAVY CHAIN; MYOSIN LIGHT CHAIN; TROPONIN I; TROPONIN T;

ARTICLE; BINDING AFFINITY; CALCIUM BINDING; CALCIUM CELL LEVEL; CELL MATURATION; CELL STRUCTURE; COMPARATIVE STUDY; EXCITATION CONTRACTION COUPLING; GENE MUTATION; GENETIC DISORDER; HEART DISEASE; HEART MUSCLE CONTRACTILITY; HUMAN; IN VITRO STUDY; KINETICS; MATHEMATICAL ANALYSIS; MATHEMATICAL MODEL; MOLECULAR MODEL; MUSCLE CELL; MUSCLE TWITCH; MYOFILAMENT; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STEM CELL DERIVED CARDIAC MYOCYTE; TISSUE ENGINEERING;

EID: 84934960294     PISSN: None     EISSN: 11772719     Source Type: Journal    
DOI: 10.4137/BMIMI.S23912     Document Type: Article

References (140)

1. Barad L, Schick R, Zeevi-Levin N, Itskovitz-Eldor J, Binah O. Human embry­onic stem cells vs human induced pluripotent stem cells for cardiac repair. Can J Cardiol. 2014;30(11):1279–87.
2. Mercola M, Colas A, Willems E. Induced pluripotent stem cells in cardiovascu­lar drug discovery. Circ Res. 2013;112(3):534–48.
3. Sallam K, Kodo K, Wu JC. Modeling inherited cardiac disorders. Circ J. 2014;78(4):784–94.
4. Karakikes I, Termglinchan V, Wu JC. Human-induced pluripotent stem cell models of inherited cardiomyopathies. Curr Opin Cardiol. 2014;29(3):214–9.
5. Liu Z, Zhou J, Wang H, Zhao M, Wang C. Current status of induced pluripo­tent stem cells in cardiac tissue regeneration and engineering. Regener Medicine Research. 2013;1(1):6.
6. Anderson P. Thin filament regulation in development. In: Solaro RJ, Moss RL, eds. Molecular Control Mechanisms in Striated Muscle. 2002nd ed. Berlin: Springer Science & Business Media; 2002:329–77.
7. Murphy A. Contractile protein phenotypic variation during development. Cardiovasc Res. 1996;31 (suppl 1):E25–33.
8. Stoehr A, Neuber C, Baldauf C, et al. Automated analysis of contractile force and Ca2+ transients in engineered heart tissue. Am J Physiol Heart Circ Physiol. 2014;306(9):H1353–63.
9. Hirt MN, Boeddinghaus J, Mitchell A, et al. Functional improvement and mat­uration of rat and human engineered heart tissue by chronic electrical stimula­tion. J Mol Cell Cardiol. 2014;74:151–61.
10. Zhang D, Shadrin IY, Lam J, Xian H-Q, Snodgrass HR, Bursac N. Tissue-engineered cardiac patch for advanced functional maturation of human ESC-derived cardiomyocytes. Biomaterials. 2013;34(23):5813–20.
11. Turnbull IC, Karakikes I, Serrao GW, et al. Advancing functional engineered cardiac tissues toward a preclinical model of human myocardium. FASEB J. 2014;28(2):644–54.
12. Tiburcy M, Didié M, Boy O, et al. Terminal differentiation, advanced orga­notypic maturation, and modeling of hypertrophic growth in engineered heart tissue. Circ Res. 2011;109(10):1105–14.
13. Christoforou N, Liau B, Chakraborty S, Chellapan M, Bursac N, Leong KW. Induced pluripotent stem cell-derived cardiac progenitors differentiate to cardio­myocytes and form biosynthetic tissues. PLoS One. 2013;8(6):e65963.
14. Nunes S, Miklas J, Liu J, Aschar-Sobbi R. Biowire: a platform for matura­tion of human pluripotent stem cell-derived cardiomyocytes. Nat Methods. 2013;10(8):781–7.
15. Lieu DK, Fu JD, Chiamvimonvat N, et al. Mechanism-based facilitated matu­ration of human pluripotent stem cell-derived cardiomyocytes. Circ Arrhythm Electrophysiol. 2013;6(1):191–201.
16. Kensah G, Roa Lara A, Dahlmann J, et al. Murine and human pluripotent stem cell-derived cardiac bodies form contractile myocardial tissue in vitro. Eur Heart J. 2013;34(15):1134–46.
17. Lan F, Lee A, Liang P, Sanchez-Freire V. Abnormal calcium handling proper­ties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells. Cell Stem Cell. 2013;12(1):101–13.
18. Sun N, Yazawa M, Liu J, et al. Patient-specific induced pluripotent stem cells as a model for familial dilated cardiomyopathy. Sci Transl Med. 2012;4(130):1–14.
19. Zhao Q, Cai H, Zhan Y, Li B, Hu S, Sun N. Applications of human-induced pluripotent stem cells in the investigation of inherited cardiomyopathy. Int J Car­diol. 2014;177(2):604–6.
20. Li M, Suzuki K, Kim NY, Liu G-H, Izpisua Belmonte JC. A cut above the rest: targeted genome editing technologies in human pluripotent stem cells. J Biol Chem. 2014;289(8):4594–9.
21. Caspi O, Huber I, Gepstein A, et al. Modeling of arrhythmogenic right ventricular cardiomyopathy with human induced pluripotent stem cells. Circ Cardiovasc Genet. 2013;6(6):557–68.
22. Ma D, Wei H, Lu J, et al. Generation of patient-specific induced pluripotent stem cell-derived cardiomyocytes as a cellular model of arrhythmogenic right ventricular cardiomyopathy. Eur Heart J. 2013;34(15):1122–33.
23. Kim C, Wong J, Wen J, et al. Studying arrhythmogenic right ventricular dyspla­sia with patient-specific iPSCs. Nature. 2013;494(7435):105–10.
24. Fatima A, Xu G, Shao K, et al. Cellular physiology biochemistry and biochemis­try in vitro modeling of ryanodine receptor 2 dysfunction using human induced pluripotent stem cells. Cell Physiol Biochem. 2011;28:579–92.
25. Jung CB, Moretti A, Mederos y Schnitzler M, et al. Dantrolene rescues arrhyth­mogenic RYR2 defect in a patient-specific stem cell model of catecholaminergic polymorphic ventricular tachycardia. EMBO Mol Med. 2012;4(3):180–91.
26. Novak A, Barad L, Zeevi-Levin N, et al. Cardiomyocytes generated from CPVTD307H patients are arrhythmogenic in response to β-adrenergic stimula­tion. J Cell Mol Med. 2012;16(3):468–82.
27. Aggarwal P, Turner A, Matter A, et al. RNA expression profiling of human iPSC-derived cardiomyocytes in a cardiac hypertrophy model. PLoS One. 2014;9(9):e108051.
28. Dick E, Kalra S, Anderson D. Exon skipping and gene transfer restore dystro­phin expression in hiPSC-cardiomyocytes harbouring DMD mutations. Stem Cells Dev. 2013;22(20):2714–24.
29. Tse HF, Ho JC, Choi SW, et al. Patient-specific induced-pluripotent stem cells-derived cardiomyocytes recapitulate the pathogenic phenotypes of dilated cardi­omyopathy due to a novel DES mutation identified by whole exome sequencing. Hum Mol Genet. 2013;22(7):1395–403.
30. Lee YK, Ho PW, Schick R, et al. Modeling of Friedreich ataxia-related iron overloading cardiomyopathy using patient-specific-induced pluripotent stem cells. Pflugers Arch. 2014;466(9):1831–44.
31. Kobayashi J, Yoshida M, Tarui S, et al. Directed differentiation of patient-specific induced pluripotent stem cells identifies the transcriptional repression and epigenetic modification of NKX2–5, HAND1, and NOTCH1 in hypoplas­tic left heart syndrome. PLoS One. 2014;9(7):e102796.
32. Zhang M, D’Aniello C, Verkerk AO, et al. Recessive cardiac phenotypes in induced pluripotent stem cell models of Jervell and Lange-Nielsen syndrome: disease mechanisms and pharmacological rescue. Proc Natl Acad Sci U S A. 2014;111(50):E5383–92.
33. Carvajal-Vergara X, Sevilla A, D’Souza SL, et al. Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome. Nature. 2010;465(7299):808–12.
34. Itzhaki I, Maizels L, Huber I, et al. Modelling the long QT syndrome with induced pluripotent stem cells. Nature. 2011;471(7337):225–9.
35. Moretti A, Bellin M, Welling A. Patient-specific induced pluripotent stem-cell models for long-QT syndrome. N Engl J Med. 2010;363(15):1397–409.
36. Matsa E, Rajamohan D, Dick E, et al. Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QT syn­drome type 2 mutation. Eur Heart J. 2011;32(8):952–62.
37. Yazawa M, Hsueh B, Jia X, et al. Using induced pluripotent stem cells to investi­gate cardiac phenotypes in Timothy syndrome. Nature. 2011;471(7337):230–4.
38. Eschenhagen T, Mummery C, Knollmann B. Modeling sarcomeric cardiomyo­pathies in the dish – from human heart samples to iPSC cardiomyocytes. Cardio­vasc Res. 2015;105(4):424–38.
39. Metzger J, Lin W, Samuelson L. Transition in cardiac contractile sensitivity to calcium during the in vitro differentiation of mouse embryonic stem cells. J Cell Biol. 1994;126(3):701–11.
40. Robertson C, Tran DD, George SC. Concise review: maturation phases of human pluripotent stem cell-derived cardiomyocytes. Stem Cells. 2013;31(5):829–37.
41. Yang X, Pabon L, Murry CE. Engineering adolescence: maturation of human pluripotent stem cell-derived cardiomyocytes. Circ Res. 2014;114(3):511–23.
42. Cao F, Wagner RA, Wilson KD, et al. Transcriptional and functional pro­filing of human embryonic stem cell-derived cardiomyocytes. PLoS One. 2008;3(10):e3474.
43. Xu XQ, Soo SY, Sun W, Zweigerdt R. Global expression profile of highly enriched cardiomyocytes derived from human embryonic stem cells. Stem Cells. 2009;27:2163–74.
44. Binah O, Dolnikov K, Sadan O, et al. Functional and developmental proper­ties of human embryonic stem cells-derived cardiomyocytes. J Electrocardiol. 2007;40(6 suppl):S192–6.
45. Dolnikov K, Shilkrut M, Zeevi-Levin N, et al. Functional properties of human embryonic stem cell-derived cardiomyocytes: intracellular Ca2+ handling and the role of sarcoplasmic reticulum in the contraction. Stem Cells. 2006;24:236–45.
46. Fu JD, Li J, Tweedie D, et al. Crucial role of the sarcoplasmic reticulum in the developmental regulation of Ca2+ transients and contraction in cardiomyocytes derived from embryonic stem cells. FASEB J. 2006;21:1–21.
47. Lieu DK, Liu J, Siu CW, et al. Absence of transverse tubules contributes to non-uniform Ca(2+) wavefronts in mouse and human embryonic stem cell-derived cardiomyocytes. Stem Cells Dev. 2009;18(10):1493–500.
48. Bers D. Cardiac excitation-contraction coupling. Nature. 2002;415(6868):198–205.
49. Kang J, Chen X, Ji J, Lei Q, Rampe D. Ca2+ channel activators reveal differential L-type Ca2+ channel pharmacology between native and stem cell-derived cardio­myocytes. J Pharmacol Exp Ther. 2012;341(2):510–7.
50. Lee YK, Ng KM, Lai WH, et al. Calcium homeostasis in human induced pluri­potent stem cell-derived cardiomyocytes. Stem Cell Rev. 2011;7(4):976–86.
51. Habib M, Caspi O, Gepstein L. Human embryonic stem cells for cardiomyogen­esis. J Mol Cell Cardiol. 2008;45(4):462–74.
52. Hattori F, Chen H, Yamashita H, et al. Nongenetic method for purifying stem cell-derived cardiomyocytes. Nat Methods. 2010;7(1):61–6.
53. Jonsson MK, Vos MA, Mirams GR, et al. Application of human stem cell-derived cardiomyocytes in safety pharmacology requires caution beyond hERG. J Mol Cell Cardiol. 2012;52(5):998–1008.
54. Zhu R, Blazeski A, Poon E, Costa K. Physical developmental cues for the maturation of human pluripotent stem cell-derived cardiomyocytes. Stem Cell Res Ther. 2014;5(117):1–18.
55. Yang X, Rodriguez M, Pabon L, et al. Tri-iodo-l-thyronine promotes the matu­ration of human cardiomyocytes-derived from induced pluripotent stem cells. J Mol Cell Cardiol. 2014;72:296–304.
56. Lundy SD, Zhu W-Z, Regnier M, Laflamme MA. Structural and functional maturation of cardiomyocytes derived from human pluripotent stem cells. Stem Cells Dev. 2013;22(14):1991–2002.
57. Rangarajan S, Madden L, Bursac N. Use of flow, electrical, and mechani­cal stimulation to promote engineering of striated muscles. Ann Biomed Eng. 2014;42(7):1391–405.
58. Parker KK, Ingber DE. Extracellular matrix, mechanotransduction and struc­tural hierarchies in heart tissue engineering. Philos Trans R Soc Lond B Biol Sci. 2007;362(1484):1267–79.
59. Schaaf S, Shibamiya A, Mewe M, et al. Human engineered heart tissue as a versatile tool in basic research and preclinical toxicology. PLoS One. 2011;6(10):e26397.
60. Hirt MN, Hansen A, Eschenhagen T. Cardiac tissue engineering: state of the art. Circ Res. 2014;114(2):354–67.
61. Soong PL, Tiburcy M, Zimmermann W-H. Cardiac differentiation of human embryonic stem cells and their assembly into engineered heart muscle. Curr Protoc Cell Biol. 2012;Chapter 23:23.8.1–21.
62. Tulloch NL, Muskheli V, Razumova MV, et al. Growth of engineered human myocardium with mechanical loading and vascular coculture. Circ Res. 2011;109(1):47–59.
63. Morgan KY, Black LD. Mimicking isovolumic contraction with combined elec­tromechanical stimulation improves the development of engineered cardiac con­structs. Tissue Eng Part A. 2014;20(11):1654–67.
64. Mulieri L, Hasenfuss G, Leavitt B. Altered myocardial force-frequency relation in human heart failure. Circulation. 1992;85:1743–51.
65. Milani-Nejad N, Janssen PML. Small and large animal models in cardiac contrac­tion research: advantages and disadvantages. Pharmacol Ther. 2014;141(3):235–49.
66. Wiegerinck R, Cojoc A, Zeidenweber C. Force frequency relationship of the human ventricle increases during early postnatal development. Pediatr Res. 2009;65(4):414–9.
67. Holubarsch C, Goulette R, Litten R, Martin B, Mulieri L, Alpert N. The economy of isometric force development, myosin isoenzyme pattern and myo­fibrillar ATPase activity in normal and hypothyroid rat myocardium. Circ Res. 1985;56:78–86.
68. McNally E, Kraft R. Full-length rat alpha and beta cardiac myosin heavy chain sequences: comparisons suggest a molecular basis for functional differences. J Mol Biol. 1989;210:665–71.
69. Yamauchi-Takihara K. Characterization of human cardiac myosin heavy chain genes. Proc Natl Acad Sci U S A. 1989;86(5):3504–8.
70. Allen DL, Leinwand LA. Postnatal myosin heavy chain isoform expression in normal mice and mice null for IIb or IId myosin heavy chains. Dev Biol. 2001;229(2):383–95.
71. Lowes BD, Minobe W, Abraham WT, et al. Changes in gene expression in the intact human heart. Downregulation of alpha-myosin heavy chain in hypertro­phied, failing ventricular myocardium. J Clin Invest. 1997;100(9):2315–24.
72. Lompre A, Nadal-Ginard B, Mahdavi V. Expression of the cardiac ventricular alpha-and beta-myosin heavy chain genes is developmentally and hormonally regulated. J Biol Chem. 1984;259(10):6437–46.
73. Lyons G, Schiaffino S. Developmental regulation of myosin gene expression in mouse cardiac muscle. J Cell Biol. 1990;111(6):2427–36.
74. Lompre A, Schwartz K, D’Albis A. Myosin isoenzyme redistribution in chronic heart overload. Nature. 1979;282:105–7.
75. Izumo S, Lompré AM, Matsuoka R, et al. Myosin heavy chain messenger RNA and protein isoform transitions during cardiac hypertrophy. J Clin Invest. 1987;79(3):970–7.
76. Gustafson T, Bahl J. Hormonal regulation of myosin heavy chain and alpha-actin gene expression in cultured fetal rat heart myocytes. J Biol Chem. 1987;262(27):13316–22.
77. Hirt MN, Sörensen NA, Bartholdt LM, et al. Increased afterload induces pathological cardiac hypertrophy: a new in vitro model. Basic Res Cardiol. 2012;107(6):307.
78. Reiser P, Portman M. Human cardiac myosin heavy chain isoforms in fetal and failing adult atria and ventricles. Am J Physiol Heart and Circ Physiol. 2001;2357:1814–20.
79. Schiaffino S, Gorza L, Saggin L, Valfre C, Sartore S. Myosin changes in hyper­trophied human atrial and ventricular myocardium. A correlated immuno-fluorescence and quantitative immunochemical study on serial. Eur Heart J. 1984;75:95–102.
80. Simon JN, Tardiff JC, Wolska BM. Sarcomeres and the biophysics of the failing heart. In: Solaro RJ, Tardiff JC, eds. Biophysics of the Failing Heart: Physics and Biology of Heart Muscle. New York, NY: Springer; 2013:225–47.
81. Mercadier JJ, Bouveret P, Gorza L, et al. Myosin isoenzymes in normal and hypertrophied human ventricular myocardium. Circ Res. 1983;53:52–63.
82. Bouvagnet P, Mairhofer H, Leger JOC, Puech P, Leger JJ. Distribution pattern of α and β myosin in normal and diseased human ventricular myocardium. Basic Res Cardiol. 1989;84:91–102.
83. Miyata S, Minobe W. Myosin heavy chain isoform expression in the failing and nonfailing human heart. Circ Res. 2000;86:386–91.
84. Nakao K, Minobe W, Roden R. Myosin heavy chain gene expression in human heart failure. J Clin Invest. 1997;100(9):2362–70.
85. Herron T, Korte FS, McDonald KS. Loaded shortening and power output in cardiac myocytes are dependent on myosin heavy chain isoform expression. Am J Physiol Heart Circ Physiol. 2001;281:1217–22.
86. Herron TJ, McDonald KS. Small amounts of alpha- myosin heavy chain isoform expression significantly increase power output of rat cardiac myocyte fragments. Circ Res. 2002;90:1150–3.
87. Korte FS, McDonald KS. Sarcomere length dependence of rat skinned cardiac myocyte mechanical properties: dependence on myosin heavy chain. J Physiol. 2007;581(pt 2):725–39.
88. Korte F, Herron T, Rovetto MJ, McDonald KS. Power output is linearly related to MyHC content in rat skinned myocytes and isolated working hearts. Am J Physiol Heart Circ Physiol. 2005;289:801–12.
89. Winegrad S. Cardiac myosin binding protein C. Circ Res. 1999;84:1117–26.
90. Mamidi R, Chandra M. Divergent effects of α- and β-myosin heavy chain iso­forms on the N terminus of rat cardiac troponin T. J Gen Physiol. 2013;142(4):413–23.
91. Thierfelder L, Watkins H, MacRae C, et al. Alpha – tropomyosin and cardiac troponin T mutations cause familial hypettrophic cardiomyopathy: a disease of the sarcomere. Cell. 1994;77:701–12.
92. Lowey S, Lesko LM, Rovner AS, et al. Functional effects of the hypertrophic cardiomyopathy R403Q mutation are different in an alpha- or beta-myosin heavy chain backbone. J Biol Chem. 2008;283(29):20579–89.
93. Ford SJ, Mamidi R, Jimenez J, Tardiff JC, Chandra M. Effects of R92 mutations in mouse cardiac troponin T are influenced by changes in myosin heavy chain isoform. J Mol Cell Cardiol. 2012;53(4):542–51.
94. Hansen A, Eder A, Bönstrup M, et al. Development of a drug screening plat­form based on engineered heart tissue. Circ Res. 2010;107(1):35–44.
95. Miklas JW, Nunes SS, Radisic M. Engineering cardiac tissues from pluripo­tent stem cells for drug screening and studies of cell maturation. Isr J Chem. 2013;53:680–94.
96. Fatkin D, Christe ME, Aristizabal O, et al. Neonatal cardiomyopathy in mice homozygous for the Arg403Gln mutation in the α cardiac myosin heavy chain gene. J Clin Invest. 1999;103(1):147–53.
97. Rayment I, Holden HM, Whittaker M, et al. Structure of the actin-myosin complex and its implications for muscle contraction. Science. 1993;261:58–65.
98. Olsson M, Patel J, Fitzsimons D. Basal myosin light chain phosphorylation is a determinant of Ca 2+ sensitivity of force and activation dependence of the kinetics of myocardial force development. Am J Physiol Heart Circ Physiol. 2004;287:2712–8.
99. Hailstones D, Barton P, Chan-thomas P, Sasse S, Sutherlandll C, Hardemanll E. Differential regulation of the atrial isoforms of the myosin light chains during striated muscle development. J Biol Chem. 1992;267(32):23295–300.
100. Pawloski-Dahm CM, Song G, Kirkpatrick DL, et al. Effects of total replace­ment of atrial myosin light chain-2 with the ventricular isoform in atrial myo­cytes of transgenic mice. Circulation. 1998;97:1508–13.
101. Franco D, Markman M, Wagenaar G, Moorman A. Myosin light chain 2a and 2v identifies the embryonic outflow tract myocardium in the developing rodent heart. Anat Rec. 1999;254:135–46.
102. Bizy A, Guerrero-Serna G, Hu B, et al. Myosin light chain 2-based selec­tion of human iPSC-derived early vnetricular cardiac myocytes. Stem Cell Res. 2013;11(3):1335–47.
103. Wang Y, Ajtai K, Burghardt TP. Ventricular myosin modifies in vitro step-size when phosphorylated. J Mol Cell Cardiol. 2014;72:231–7.
104. Sheikh F, Ouyang K, Campbell SG, et al. Mouse and computational models link Mlc2v dephosphorylation to altered myosin kinetics in early cardiac disease. J Clin Invest. 2012;122(4):1209–21.
105. Varian KD, Janssen PML. Frequency-dependent acceleration of relaxation involves decreased myofilament calcium sensitivity. Am J Physiol Heart Circ Physiol. 2007;92:2212–9.
106. Chan JY, Takeda M, Briggs LE, et al. Identification of cardiac-specific myosin light chain kinase. Circ Res. 2008;102(5):571–80.
107. Ding P, Huang J, Battiprolu PK, Hill JA, Kamm KE, Stull JT. Cardiac myosin light chain kinase is necessary for myosin regulatory light chain phosphorylation and cardiac performance in vivo. J Biol Chem. 2010;285(52):40819–29.
108. Takeda S, Yamashita A, Maeda K, Mae Y. Structure of the core domain of human cardiac troponin in the Ca2+ -saturated form. Nature. 2003;424(7):35–41.
109. Reiser P, Westfall M, Schiaffino S, Solaro J. Tension production and thin-filament protein isoforms in developing rat myocardium. Am J Physiol Heart Circ Physiol. 1994;36:H1589–96.
110. Siedner S, Krüger M, Schroeter M, et al. Developmental changes in contractility and sarcomeric proteins from the early embryonic to the adult stage in the mouse heart. J Physiol. 2003;548(pt 2):493–505.
111. Marston SB, Redwood CS. Modulation of thin filament activation by break­down or isoform switching of thin filament proteins: physiological and patho­logical implications. Circ Res. 2003;93(12):1170–8.
112. Nassar R, Malouf NN, Kelly MB, Oakeley AE, Anderson PAW. Force-pCa rela­tion and troponin T isoforms of rabbit myocardium. Circ Res. 1991;69:1470–6.
113. Greaser M, Gergely J. Reconstitution of troponin activity from three protein components. J Biol Chem. 1971;246(18):4226–33.
114. Gordon AM, Regnier M, Homsher E. Skeletal and cardiac muscle contractile activation: tropomyosin “rocks and rolls ”. News Physiol Sci. 2001;16(4):49–55.
115. Kobayashi T, Solaro RJ. Calcium, thin filaments, and the integrative biology of cardiac contractility. Annu Rev Physiol. 2005;67:39–67.
116. Sasse S, Brand NJ, Kyprianou P, et al. Troponin I gene expression during human cardiac development and in end-stage heart failure. Circ Res. 1993;72:932–9.
117. Dong W, Chandra M, Xing J, She M, Solaro RJ, Cheung HC. Phosphorylation-induced distance change in a cardiac muscle troponin I mutant. Biochemistry. 1997;36:6754–61.
118. Fentzke RC, Buck SH, Patel JR, et al. Impaired cardiomyocyte relaxation and diastolic function in transgenic mice expressing slow skeletal troponin I in the heart. J Physiol. 1999;517(1):143–57.
119. Tachampa K, Wang H, Farman GP, De Tombe PP. Cardiac troponin I threonine 144: role in myofilament length dependent activation. Circ Res. 2007;101(11):1081–3.
120. Solaro RJ, Arteaga GM. Heart failure, ischemia/reperfusion injury and cardiac troponin. In: Ebashi S, Ohtsuki I, eds. Regulatory Mechanisms of Striated Muscle Contraction. Berlin: Springer; 2007:191–200.
121. Bedada FB, Chan SS, Metzger SK, et al. Acquisition of a quantitative, stoichio­metrically conserved ratiometric marker of maturation status in stem cell-derived cardiac myocytes. Stem cell Rep. 2014;3(4):594–605.
122. LeWinter MM, Granzier H. Cardiac titin: a multifunctional giant. Circulation. 2010;121(19):2137–45.
123. Opitz CA, Leake MC, Makarenko I, Benes V, Linke WA. Developmentally regulated switching of titin size alters myofibrillar stiffness in the perinatal heart. Circ Res. 2004;94(7):967–75.
124. Lahmers S, Wu Y, Call DR, Labeit S, Granzier H. Developmental control of titin isoform expression and passive stiffness in fetal and neonatal myocardium. Circ Res. 2004;94(4):505–13.
125. Krüger M, Linke WA. Titin-based mechanical signalling in normal and failing myocardium. J Mol Cell Cardiol. 2009;46(4):490–8.
126. Granzier HL, Labeit S. The giant protein titin: a major player in myocardial mechanics, signaling, and disease. Circ Res. 2004;94(3):284–95.
127. Nagueh SF, Shah G, Wu Y, et al. Altered titin expression, myocardial stiffness, and left ventricular function in patients with dilated cardiomyopathy. Circula­tion. 2004;110(2):155–62.
128. Krüger M, Sachse C, Zimmermann WH, Eschenhagen T, Klede S, Linke WA. Thyroid hormone regulates developmental titin isoform transitions via the phosphatidylinositol-3-kinase/AKT pathway. Circ Res. 2008;102(4):439–47.
129. Linke WA, Krüger M. The giant protein titin as an integrator of myocyte signal­ing pathways. Physiology (Bethesda). 2010;25(3):186–98.
130. Fukuda N, Wu Y, Farman G, Irving TC, Granzier H. Titin isoform variance and length dependence of activation in skinned bovine cardiac muscle. J Physiol. 2003;553(pt 1):147–54.
131. Solaro RJ, Rosevear P, Kobayashi T. The unique functions of cardiac troponin I in the control of cardiac muscle contraction and relaxation. Biochem Biophys Res Commun. 2008;369(1):82–7.
132. Campbell SG, Haynes P, Kelsey Snapp W, Nava KE, Campbell KS. Altered ven­tricular torsion and transmural patterns of myocyte relaxation precede heart failure in aging F344 rats. Am J Physiol Heart Circ Physiol. 2013;305(5):H676–86.
133. Kuo IY, Kwaczala AT, Nguyen L, Russell KS, Campbell SG, Ehrlich BE. Decreased polycystin 2 expression alters calcium-contraction coupling and changes β-adrenergic signaling pathways. Proc Natl Acad Sci U S A. 2014;111(46):16604–9.
134. Ray K, England P. Phosphorylation of the inhibitory subunit of troponin and its effect on the calcium dependence of cardiac myofibril adenosine triphosphatase. FEBS Lett. 1976;70:1.
135. Zhang R, Zhao J, Potter JD. Phosphorylation of both serine residues in cardiac troponin I is required to decrease the Ca affinity of cardiac troponin C. J Biol Chem. 1995;270(51):30773–80.
136. Rossman EI, Petre RE, Chaudhary KW, et al. Abnormal frequency-dependent responses represent the pathophysiologic signature of contractile failure in human myocardium. J Mol Cell Cardiol. 2004;36(1):33–42.
137. Haizlip KM, Milani-nejad N, Brunello L, et al. Dissociation of calcium tran­sients and force development following a change in stimulation frequency in iso­lated rabbit myocardium. Biomed Res Int. 2015;2015:12.
138. Holubarsch C, Ruf T, Goldstein DJ, et al. Existence of the Frank-Starling mechanism in the failing human heart Investigations on the organ, tissue, and sarcomere levels. Circulation. 1996;94(4):683–9.
139. Bollensdorff C, Lookin O, Kohl P. Assessment of contractility in intact ven­tricular cardiomyocytes using the dimensionless “Frank–Starling Gain”index. Pflugers Arch. 2011;462:39–48.
140. Bird SD, Doevendans PA, van Rooijen MA, Brutel de la Riviere A. The human adult cardiomyocyte phenotype. Cardiovasc Res. 2003;58:423–34.